The effect of donepezil treatment on cardiovascular mortality.

Sato K, Urbano R, Yu C, Yamasaki F, Sato T, Jordan J, Robertson D, Diedrich A
Clin Pharmacol Ther. 2010 88 (3): 335-8

PMID: 20664535 · PMCID: PMC3120840 · DOI:10.1038/clpt.2010.98

The acetylcholinesterase inhibitor donepezil hydrochloride improves cognitive function in patients with Alzheimer's disease and vascular dementia. Given acetylcholine's important actions on the heart, we undertook a retrospective cohort investigation to assess whether donepezil usage affects cardiovascular mortality. In patients treated with donepezil, hazard ratios for total and cardiovascular mortality were 0.68 (P = 0.045, 95% confidence interval 0.46-0.99) and 0.54 (P = 0.042, 95% confidence interval 0.30-0.98), respectively. The apparent survival benefit in donepezil-treated patients should not be overinterpreted. Prospective clinical trials are warranted.

MeSH Terms (17)

Aged Aged, 80 and over Alzheimer Disease Cardiovascular Diseases Cholinesterase Inhibitors Cohort Studies Dementia, Vascular Donepezil Female Follow-Up Studies Humans Indans Male Nootropic Agents Piperidines Proportional Hazards Models Retrospective Studies

Connections (1)

This publication is referenced by other Labnodes entities: